Catheters Receive OK
- Share via
IRVINE — CardioVascular Dynamics Inc. said Tuesday it has received clearance from the Food and Drug Administration to market its Focus-PV catheters, intended to treat atherosclerosis blocking blood flow within arteries of the leg and other peripheral locations. CardioVascular said the clearance allows the company to market 72 new different models of Focus-PV catheters.
The company said the catheters use low and high balloon inflation pressures.
CardioVascular develops and markets catheters and vascular access products.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
